

Estudio: **DIPLOMA DE EXPERTO EN ANTICONCEPCIÓN PARA MATRONAS**

Código Plan de Estudios: **FA27**

Año Académico: **2023-2024**

<b>ESTRUCTURA GENERAL DEL PLAN DE ESTUDIOS:</b>							
CURSO	Obligatorios		Optativos		Prácticas Externas	TFM/Memoria/ Proyecto	Créditos Totales
	Créditos	Nº Asignaturas	Créditos	Nº Asignaturas	Créditos	Créditos	
1º	18	1					18
2º							
3º							
<b>CRÉDITOS TOTALES</b>	<b>18</b>	<b>1</b>					<b>18</b>

<b>PROGRAMA TEMÁTICO:</b>				
<b>ASIGNATURAS OBLIGATORIAS</b>				
Código Asignatura	Curso	Denominación	Carácter OB/OP	Créditos
706278	1	MANEJO DE LA ANTICONCEPCIÓN PARA MATRONAS	OB	18

Carácter: OB - Obligatoria; OP – Optativa

## GUÍA DOCENTE

Año académico	2023-2024	
Estudio	Diploma de Experto en Anticoncepción para Matronas	
Nombre de la asignatura	MANEJO DE LA ANTICONCEPCIÓN PARA MATRONAS	
Carácter (Obligatoria/Optativa)	OBLIGATORIA	
Créditos (1 ECTS=25 horas)	18	
Modalidad (elegir una opción)		Presencial (más del 80% de las sesiones son presenciales)
		Híbrida (sesiones on-line entre el 40% y 60%, resto presencial)
	X	Virtual (al menos el 80% de las sesiones son on-line o virtuales)
Profesor/a responsable	M <sup>a</sup> JESÚS CANCELO HIDALGO	
Idioma en el que se imparte	CASTELLANO	

### PROFESORES IMPLICADOS EN LA DOCENCIA

ENRIQUETA BARRANCO	M <sup>a</sup> JOSÉ PUENTE
ESTHER DE LA VIUDA	MACARENA QUESADA
EZEQUIEL PÉREZ CAMPOS	MARTA CORREA
FÁTIMA LEÓN	MARTA LEGORBURU
FRANCISCA MARTÍNEZ	MODESTO REY
INMACULADA PARRA	NICOLÁS MENDOZA
ISABEL RAMÍREZ	NURIA PARERA
JOAQUÍN GARCÍA CERVERA	PALOMA LOBO
JOSÉ M <sup>a</sup> MARI JUAN	RAFAEL SÁNCHEZ BORREGO
JOSÉ VICENTE GONZÁLEZ	SERGIO HAIMOVICH
M <sup>a</sup> JESÚS ALONSO	SILVIA TAPIADOR
M <sup>a</sup> JESÚS CANCELO	

### DISTRIBUCIÓN DE CRÉDITOS (especificar en horas)

Número de horas presenciales/on-line asistencia profesor/a	150
Número de horas de trabajo personal del estudiante	300
Total horas	450

### CONTENIDOS (Temario)

SITUACIÓN ACTUAL DE LA ANTICONCEPCIÓN EN ESPAÑA Y EUROPA  
 MITOS EN ANTICONCEPCIÓN  
 ANATOMÍA DEL APARATO GENITAL FEMENINO Y MASCULINO  
 PRINCIPIOS ACTIVOS EN ANTICONCEPCIÓN Y REPRODUCCIÓN  
 PAPEL DE LAS HORMONAS EN LA SEXUALIDAD  
 REGULACIÓN DEL CICLO MENSTRUAL  
 FARMACOCINÉTICA Y FARMACODINAMIA DE AH  
 HISTORIA DE LA ANTICONCEPCIÓN

MÉTODOS NATURALES Y MÉTODOS BARRERA  
ANTICONCEPCIÓN HORMONAL COMBINADA  
ANTICONCEPCIÓN CON SOLO GESTÁGENOS  
ANTICONCEPCIÓN INTRAUTERINA  
ANTICONCEPCIÓN DE URGENCIA  
DOBLE MÉTODO  
ANTICONCEPCIÓN QUIRÚRGICA FEMENINA Y MASCULINA  
GENERALIDADES SOBRE LOS BENEFICIOS DE LOS MÉTODOS ANTICONCEPTIVOS  
INTERACCIONES MEDICAMENTOSAS EN TRATAMIENTOS HABITUALES  
CME. CONFERENCIA DE CONSENSO SEC  
ASESORAMIENTO ANTICONCEPTIVO (Requisitos para la anticoncepción)  
ASESORAMIENTO ANTICONCEPTIVO EN ITS  
ASESORAMIENTO ANTICONCEPTIVO EN LA ADOLESCENCIA  
ASESORAMIENTO ANTICONCEPTIVO EN LA PERIMENOPAUSIA  
ASESORAMIENTO ANTICONCEPTIVO EN POSTPARTO Y LACTANCIA  
ASESORAMIENTO ANTICONCEPTIVO POST-ABORTO. ESTRATEGIAS PARA EVITAR ABORTOS DE REPETICIÓN  
ASESORAMIENTO ANTICONCEPTIVO EN ALTERACIONES DE LA HEMOSTASIA Y PATOLOGÍA CARDIOVASCULAR  
ASESORAMIENTO ANTICONCEPTIVO EN ENDOCRINOPATÍAS  
ASESORAMIENTO ANTICONCEPTIVO EN MUJERES CON OBESIDAD  
EDUCACIÓN MATERNAL: ASESORAMIENTO ANTICONCEPTIVO  
LA ATENCIÓN A LA SALUD SEXUAL Y REPRODUCTIVA: SEXUALIDAD EN EMBARAZO Y PUERPERIO  
ATENCIÓN EN SITUACIONES DE VIOLENCIA DE GÉNERO  
DIVERSIDAD CULTURAL Y SSR Y ANTICONCEPCIÓN  
ANTICONCEPCIÓN Y CALIDAD DE VIDA  
CASOS CLÍNICOS

### **COMPETENCIAS ESPECÍFICAS (indicar un mínimo de tres y máximo de cinco)**

- El alumno estará capacitado para realizar un asesoramiento anticonceptivo basado en la evidencia, de forma individualizada conociendo y transmitiendo sobre los riesgos, beneficios, cumplimiento.
- El alumno estará capacitado para resolver las dudas que le planteen las usuarias en su práctica clínica.
- El alumno será capaz de realizar la historia clínica a la usuaria en anticoncepción.

### **EVALUACIÓN**

5 exámenes tipo test  
Resolución de 20 casos clínicos en anticoncepción

### **BIBLIOGRAFÍA**

United Nations Population Division. Department of Economic and Social Affairs. World Contraceptive Use 2015  
Accesible en  
<http://www.un.org/en/development/desa/population/publications/pdf/family/trendsContraceptiveUse2015Report.pdf>  
United Nations Population Division. Department of Economic and Social Affairs. World Contraceptive Use 2018  
Accesible en :

<http://www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2018.shtml>

Contraception Atlas Accesible en: <https://www.contraceptioninfo.eu/node/7>

Who Model List of Essential Medicines 20th List (March 2017) Accesible en:

[https://www.who.int/medicines/publications/essentialmedicines/20th\\_EML2017.pdf?ua=1](https://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?ua=1)

ECEC accesible en: <http://www.ec-ec.org/emergency-contraception-in-europe/emergency-contraception-availability-in-europe/> (31-1-2017)

ECEC accesible en: <http://www.ec-ec.org/emergency-contraception-in-europe/country-by-country-information-2/> (19-12-2018)

An update on access to emergency contraception in European Union Countries ECEC April 2016 Accesible en :

<http://www.ec-ec.org/custom-content/uploads/2016/04/UPDATE-Access-to-EC-in-EU-countries-ECEC-April2016.pdf>

Sedgh G. Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. *Lancet* 2016; 388: 258–67

Bearak J. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. *Lancet Glob Health* 2018; 6: e380–89

The World abortion Laws 2019. Accesible en: <http://worldabortionlaws.com>

World Health Organization. Reproductive Health and Research., World Health Organization. Family and Community Health. Selected practice recommendations for contraceptive use. World Health Organization, Reproductive Health and Research, Family and Community Health; 2005. Apter D, Zimmerman Y, Beekman L, Mawet M, Maillard C, Foidart J-M, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. *Eur. J. Contracept. Reprod. Heal. Care* [Internet]. 2017 Jul 4 [cited 2018 Nov 23];22(4):260–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28641030> Bastianelli C, Farris M, Rosato E, Brosens I, Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: Effects on metabolism. *Expert Rev. Clin. Pharmacol.* [Internet]. 2016 Dec 15 [cited 2017 Jan 24];17512433.2017.1271708. Available from: <https://www.tandfonline.com/doi/full/10.1080/17512433.2017.1271708> Dinger J, Minh T Do, Buttman N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. *Obstet. Gynecol.* [Internet]. 2011 Jan [cited 2018 Nov 18];117(1):33–40. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21213475> Duijkers IJM, Klipping C, Zimmerman Y, Appels N, Jost M, Maillard C, et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study. *Eur. J. Contracept. Reprod. Health Care* [Internet]. 2015 [cited 2018 Nov 23];20(6):476–89. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26394847> Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. *Contraception* [Internet]. 2010 Oct [cited 2018 Nov 18];82(4):314–23. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20851224> Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. *Cochrane Database Syst. Rev.* [Internet]. 2013 Aug 1 [cited 2018 Nov 18];(8):CD003989. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23904209> Gourdy P, Guillaume M, Fontaine C, Adlanmerini M, Montagner A, Laurell H, et al. Estrogen receptor subcellular localization and cardiometabolism. *Mol. Metab.* [Internet]. Elsevier; 2018 Sep 1 [cited 2018 Nov 23];15:56–69. Available from: <https://www.sciencedirect.com/science/article/pii/S2212877818302771> Grandi G, Facchinetti F, Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? *Eur. J. Contracept. Reprod. Heal. Care* [Internet]. 2017 Jul 4 [cited 2018 Nov 18];22(4):245–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28902531> Jusko WJ. Clarification of contraceptive drug pharmacokinetics in obesity. *Contraception* [Internet]. 2017a Jan [cited 2018 Nov 18];95(1):10–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27542520> Jusko WJ. Perspectives on variability in pharmacokinetics of an oral contraceptive product. *Contraception* [Internet]. 2017b Jan [cited 2018 Nov 18];95(1):5–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27475034> Lackie E, Fairchild A. The birth control pill, thromboembolic disease, science and the media: a historical review of the relationship. *Contraception*. 2016. De Leo V, Musacchio MC, Cappelli V, Piomboni P, Morgante G. Hormonal contraceptives: pharmacology tailored to women's health. *Hum. Reprod. Update* [Internet]. 2016 Sep [cited 2017 Jan 24];22(5):634–46. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27307386> London A, Jensen JT. Rationale for eliminating the hormone-free interval in modern oral contraceptives. *Int. J. Gynaecol. Obstet.* [Internet]. 2016 Jul [cited 2018 Nov 18];134(1):8–12. Available from: <http://doi.wiley.com/10.1016/j.ijgo.2015.10.028> Mueck AO, Sitruk-Ware R. Norgestrel acetate, a novel progestogen for oral contraception. *Steroids* [Internet]. 2011 May [cited 2018 Nov 18];76(6):531–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21335021> Narayan P, Ulloa-Aguirre A, Dias JA. Gonadotropin Hormones and Their Receptors. *Yen Jaffe's Reprod. Endocrinol.* [Internet]. Content Repository Only!; 2019 Jan 1 [cited 2018 Nov 23];25– 57.e15. Available from: <https://www.sciencedirect.com/science/article/pii/B978032347912700020> Nelson

- AL. Transdermal contraception methods: today's patches and new options on the horizon. *Expert Opin. Pharmacother.* [Internet]. 2015 Apr 13 [cited 2018 Nov 18];16(6):863–73. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25800084>
- Regidor P-A. Clinical relevance in present day hormonal contraception. *Horm. Mol. Biol. Clin. Investig.* [Internet]. 2018a Oct 26 [cited 2018 Nov 18];0(0). Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30367791>
- Regidor P-A. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. *Oncotarget* [Internet]. 2018b Oct 2 [cited 2018 Nov 16];9(77):34628–38. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30349654>
- Sitruk-Ware R, Nath A. The use of newer progestins for contraception. *Contraception* [Internet]. 2010 Nov [cited 2018 Nov 18];82(5):410–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20933114>
- Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. *Rev. Endocr. Metab. Disord.* [Internet]. 2011 Jun 3 [cited 2018 Nov 18];12(2):63–75. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21538049>
- Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. *Best Pract. Res. Clin. Endocrinol. Metab.* [Internet]. 2013a Feb [cited 2018 Nov 18];27(1):13–24. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23384742>
- Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. *Best Pract. Res. Clin. Endocrinol. Metab.* [Internet]. 2013b Feb [cited 2018 Nov 16];27(1):13–24. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23384742>
- Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17 $\beta$ -estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. *Contraception* [Internet]. Elsevier; 2013 Jun 1 [cited 2018 Nov 18];87(6):706–27. <http://www.who.int/reproductivehealth/en/>. OMS. 5th Edition MEC [http://apps.who.int/iris/bitstream/10665/205016/1/WHO\\_RHR\\_15.07\\_spa.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/205016/1/WHO_RHR_15.07_spa.pdf?ua=1) Resumen ejecutivo de la 5ª ed, Criterios médicos de elegibilidad para la elección de método anticonceptivo [http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1). Medical Eligibility Criteria for contraceptive use <http://www.who.int/rh/es/> OMS. La biblioteca de Salud Reproductiva <http://www.who.int/rhl/fertility/contraception/es/> OMS. La biblioteca de Salud Reproductiva. Contracepción [http://www.who.int/rhl/fertility/contraception/mec\\_story/es/](http://www.who.int/rhl/fertility/contraception/mec_story/es/) OMS. La biblioteca de Salud Reproductiva. Criterios de elegibilidad médica de la OMS para el uso de anticonceptivos [http://www.fsrh.org/pages/clinical\\_guidance.asp](http://www.fsrh.org/pages/clinical_guidance.asp) FSRH is a faculty of the Royal College of Obstetricians and Gynaecologists established in 1997 as the Faculty of Sexual and Reproductive Healthcare. <https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html> US Medical Eligibility Criteria (US MEC) for Contraceptive Use, 2016
- 1 -Abrams LS, Skee DM, Natarajan J, Hutman W, Wong FA. Tetracycline HCL does not affect the pharmacokinetics of a contraceptive patch. *Int J GynaecolObstet* 2000; 70(Suppl. 1): 57–58.
  - 2 -AIDS info. Guidelines for the use of antiretroviral agents in HIV-1 Infected adults and adolescents. <https://aidsinfo.nih.gov/guidelines> on 12/1/2018
  - 3 -Back DJ, Breckenridge AM, Crawford FE, Hall JM, MacIver M, et al.The effect of rifampicin on the pharmacokinetics of ethinylestradiol in women. *Contraception* 1980;21:135-143.
  - 4-Back DJ, Grimmer SfM, Orme MLE, Proudlove C, Mann RD, Breckenridge AM. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. *Br J Clin Pharmacol* 1988; 25: 527–532.
  - 5-Bainton R. Interaction between antibiotic therapy and contraceptive medication. *Oral Surg Oral Med Oral Pathol Oral RadiolEndod* 1986; 61: 453–455.
  - 6-Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, et al.The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. *Clin Pharmacol Ther* 1999; 65:428–438.
  - 7-Berry-Bibee EN, et al. Co-administration of St. John's and hormonal contraceptives: a systematic review. *Contraception*;94(2016): 668-677.
  - 8-Berry-Bibee EN, et al. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. *Contraception* Dec ; 94(2016): 650-667.
  - 9-- Bollen M. Use of antibiotics when taking the oral contraceptive pill. *Aust Fam Physician* 1995; 24: 928–929.
  - 10 –Instituto Catalán de la Salud. Comité de evaluación de nuevos Medicamentos. Ulipristal.– CANM número 8, Octubre 2010.
  - 11- Christian Manzardo , Montserrat Tuset, Jose M. Miró, , Jose M. Gatell.. Interacciones graves o potencialmente letales entre antirretrovirales y otros medicamentos. *Enfermedades infecciosas y microbiología clínica.* Vol 33 ;Nº 17 (2015): 435-504
  - 12-Csemiczky G, Alvendal C, Landgren BM. Risk for ovulation in women taking a low-dose oral contraceptive

- (Microgynon) when receiving antibacterial treatment with fluoroquinolone (ofloxacin). *AdvContracept* 1996; 12: 101–109.
- 13- Chappell CA, Lasmorde N, Nakalema S et al. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. *AIDS* 2017 Sep 10;31(14):1965-1972.
- 14- Chappell C. Efavirenz — but not nevirapine — based antiretroviral therapy significantly reduces etonogestrel concentrations among HIV-positive women using subdermal contraceptive implants. *Contraception* 2016 94(4):390
- 15-Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring Nuvaring with oral amoxicillin or doxycycline in two randomised trials. *Clin Pharmacokinet* 2005; 44: 429–438
- 16-Donley TG, Smith RF, Roy B. Reduced oral contraceptive effectiveness with concurrent antibiotic use: a protocol for prescribing antibiotics to women of childbearing age. *Compendium* 1990; 11: 392–396.
- 17-Dossetor J. Drug interactions with oral contraceptives. *BMJ* 1984; 4: 467–468.
- 18 -Edelman A, Gallo MF, Jensen JT, Nichols MD, Grimes DA. Continuous or extended cycles vs. cyclic use of combined hormonal contraceptives for contraception. *Cochrane Database System Rev* 2005, 3:CD004695. DOI: 10.1002/14651858.CD004695.pub2
- 19 -Faculty of Family Planning and Reproductive Health Care. Drug Interactions with Hormonal Contraception (January 2011). Faculty of Sexual and Reproductive Healthcare – Clinical Effectiveness Unit, January 2011. [accesible online en [www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf](http://www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf),
- 20 -Faculty of Family Planning and Reproductive Health Care. Clinical Guidance:Drug Interactions with Hormonal Contraception (January 2018)
- 21-García P, Martínez F, Pintor A, Caelles N e Ibañez J. Guía Sandoz de utilización de medicamentos. Anticonceptivos hormonales. Uni Granada. 2006:28-34
- 22-Joint Formulary Committee. British National Formulary (BNH 59). 2010
- 23-Joshi JV, Joshi UM, Sankolli GM, Gupta K, Rao AP, Hazari K, et al. A study of interaction of a low-dose contraceptive with anti-tubercular drugs. *Contraception* 1980; 21: 617–629.
- 24- Jusko WJ. Perspectives on variability in pharmacokinetics of an oral contraceptive product. *Contraception* 95(2017):5-9
- 25-Katabian L. IX Congreso AMADA Obt –Gin 2012. Córdoba. Argentina . Disponible en [https://www.youtube.com/watch?v=\\_BIZNLo0CuM](https://www.youtube.com/watch?v=_BIZNLo0CuM)
- 26- Kourtis AP, Mirza A. Contraception for HIV- Infected Adolescents. *Pediatrics*. 2016 Sep; 138(3). Pii:e20161802. Doi:10.1542/peeds.2016-1892.
- 27- Landolt NK, Phanuphak N, Ubolyam S, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. *J Acquir Immune Defic Syndr*. 2013;62(5):534–539.
- 28- Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. *Contraception* 95(2017) 571-577
- 29-LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, et al. Effects of rifabutin and rifampicin on pharmacokinetics of ethinylestradiol and norethindrone. *J Clin Pharmacol* 1998; 38: 1042–1050.
- 30- Leticee N et al. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. *Contraception* 85 (2012) 425–427
- 31- Martín Auriolos E, De la Cruz Cortés JP, González Correa JA. Antibióticos y anticonceptivos: ¿una interacción relevante? *Actualidad en Farmacología y Terapéutica*. Marzo 2011, vol9 nº 1:43-45.
- 32-Meadows M. Preventing serious Drug Interactions. *FDA Consumer*, jul/Aug 2004, vol.38 Issue 4, p 12-17, 6p, 3c.
- 33- Menon S, Riese R Wang R et al. Evaluation of the effect of Tofacitinib on the pharmacokinetics of oral contraceptive steroids in healthy female volunteers. *Clinical Pharmacology in drug Development* 2016,5(5):336-342
- 34- Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/ norethindrone when administered concurrently to HIV-infected women. *J Acquir Immune Defic Syndr*. 2002;29(5):471–477
- 35- Moltó J. Guía de interacciones medicamentosas de interés en el paciente infectado por el VIH, 2ª Edición 2016. Fundación lucha contra el SIDA.



- 36-Murphy AA, Zacur HA, Charace P, Burkman RT. The effect of tetracycline on level of oral contraceptives. *Am J ObstetGynecol* 1991; 164: 28–33.
- 37- Nanda K, Delany-Moretlwe S, Dubé K, et al. Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness. *AIDS*. 2013;27(suppl 1):S17–S25
- 38-Neely JL, Abate M, Swinker M, D’Angio R. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. *ObstetGynecol* 1991; 77: 416–420.
- 39- OMS 2010 World Health Organization. Medical eligibility criteria for contraceptive use – 4th ed. 2010.
- 40- OMS 2015 World Health Organization. Medical eligibility criteria for contraceptive use – 5th ed. 2015.
- 41-Reimers A et al. . Interactions between hormonal contraception and antiepileptic drugs: Clinical and mechanistic considerations. *Seizure* ; 28 (2015): 66-70.
- 42- Reitelr L, Nakken KO. Contraception for women taking antiepileptic drugs. *Tidsskr Nor Laegeforen*. 2016 Jan 12;136(1):32-4.
- 43- Scholten PC, Droppert RM, Zwinkels MGL, Moesker HL, Nauta JJP, Hoepelman IM. No interaction between ciprofloxacin and an oral contraceptive. *Antimicrob Agents Chemother* 1998; 42: 3266–3268.
- 44- Schwartz J, Hunt T, Smith WB, Wong P, Larson P, Crumley T, et al. The effect of etoricoxib on the pharmacokinetics or oral contraceptive in healthy participants. *J Clin Pharmacol* 2009; 49: 807–815.
- 45-Sidhu J, Job S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. *Br J Pharmacol* 2005; 61: 191–199.
- 46- Simmons KB et al. . Effect of concurrent vaginal miconazole treatment on the absorption and exposure of Nesterone and Etiln estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study. *Contraception* 97 (2018) 270-276.
- 47- Scarsi et al. drug-drug interactions, Effectiveness, and safety of hormonal contraceptives in women living with HIV. *Drug Saf*. 2016 Nov; 39(11): 1053-1072.
- 48- Sociedad Española de Farmacia Hospitalaria: SEFH. Introducción a las interacciones farmacológicas. 1ª Ed. 2014. Versión digital disponible en: [www.sefh.es](http://www.sefh.es)
- 49- .Stuart GS, Moses A, Corbett A, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. *J Acquir Immune Defic Syndr*. 2011;58(2):e40–e43.
- 50-Sujatha Menon, Richard Riese, Ronnie Wang, et al. Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. *Clinical Pharmacology in Drug Development* 2016, 5(5): 336–342.
- 51-Torres Serna C. Anticonceptivos hormonales y su interacción con otros medicamentos. *ANTICONCEPCIÓN EN SITUACIONES ESPECIALES*. 2006. Cap 34
- 52- University of Liverpool. HIV drug-interactions. [www.hiv-druginteractions.org/Charts](http://www.hiv-druginteractions.org/Charts) reviewed October 2018.
- 53- Hongjian Zhang, Donghui Cui, Bonnie Wang et al. Pharmacokinetic Drug Interactions Involving 17 $\alpha$ -Ethinylestradiol. A New Look at an Old Drug. *Clin Pharmacokinet* 2007; 46 (2): 133-157.
- 54-Zhang H et al. Pharmacokinetic Drugs Interactions Involving 17 alpha-Ethinylestradiol: A new look at an Old Drug. *Clin Pharmacokinet* 46(2)2007:133-157.
- 55-Zucchero F, Hogan M. Pocket Guide to Evaluation of Drug Interactions. American Pharmacists Association, 5ª Ed. 2004, FÁRMACOS UTILIZADOS EN LA INDUCCIÓN DEL ABORTO FARMACOLÓGICO
- Flores, J.; Armijo, J.A.; Mediavilla, A. *Farmacología Humana*. Masson- Salvat. 5ª Edición. 2008.
- Hardman, J.G.; Limbird, L.E. Goodman y Gilman. *Bases Farmacológicas de la Terapéutica*. Mc Graw Hill Interamericana. 2 volúmenes. 10ª Edición. 2001.
- Brunton, L; Parker, K; Blumenthal, D; Buxton, I. Goodman y Gilman. *Manual de farmacología y terapéutica*. Mc Graw Hill. 2009.
- Lorenzo, P.; Moreno, A.; Leza, J.C.; Lizasoain, I.; Moro, M.A Velásquez. *Farmacología básica y clínica*. Ed. Panamericana, 17ª Edición. 2005.
- Raffa, R; Rawls, S; Portyansky Beyzarov, E. Netter. *Farmacología ilustrada*. Elsevier Masson. 1ª Edición. 2008
- López Castellano, A; Moreno Royo, L; Vilaagrasa Sebastián, V. *Manual de Farmacología. Guía para El uso racional Del*

mediocamento. Elsevier. 2006

Malgor, L.A.; Valsecia, M. Farmacología Médica. 2ª Edición. 2000. 5 volúmenes. Soporte electrónico disponible en: <http://med.unne.edu.ar/farmaco.html>

Neal, M.J. Farmacología médica en esquemas. CTM. Servicios Bibliográficos S.A. 4ª Edición. 2003.

PR Vademécum. 13ª Edición. E.C.S.A. Argentina. 2006.

El Manual Merk de Diagnóstico y Tratamiento. Harcourt. 10ª Edición. 1999.

Diccionario de Medicina Océano Mosby. 4ª Edición. 1999.

Stanley L Robins. Patología estructural y funcional. Editorial Interamericana. 1998. Bovill J. Engbers F.

Pharmacodynamics of drug action en: Bovill J. Howie M. eds. Clinical pharmacology for anaesthetists. 1st ed. London. W B Saunders, 1999: 35-43.

Cicccone G. Holdcroft A. Drugs and sex differences: a review of drugs relating to anesthesia. Br J Anaesth. 1999; 82: 255-65.

Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000 Apr; 107(4):519-23.

Capilla Montes C, Bermejo Vicedo T. Eficacia y seguridad de misoprostol en obstetricia. Farm Hosp 2005; 29: 177-184

Carbonell JL, Varela L, Velazco A, Cabezas E, Fernandez C, Sanchez C. Oral methotrexate and vaginal misoprostol for early abortion. Contraception 1998;57:83-8.

Carbonell Esteve JL, Varela L, Velazco A, Tanda R, Sanchez C. 25 mg Or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion: a randomized trial.

Gynecol Obstet Invest 1999;47:182-7.

Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod 2004;19:81-84.

Aronsson A, Fiala C, Stephansson O, Granath F, Watzter B, Schweer H, Gemzell-Danielsson K. Pharmacokinetic profiles up to 12h after administration of vaginal, sublingual and slow-release oral misoprostol. Hum Reprod 2007;22:1912-1918

World Health Organization. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993;307:532-537.

Uso de misoprostol en Ginecología y Obstetricia. Manual FLASOG. Tercera edición. 2013.